|
1
|
Murphy M, Crean J, Brazil DP, Sadlier D,
Martin F and Godson C: Regulation and consequences of differential
gene expression in diabetic kidney disease. Biochem Soc Trans.
36:941–945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stitt-Cavanagh E, MacLeod L and Kennedy C:
The podocyte in diabetic kidney disease. ScientificWorldJournal.
14:1127–1139. 2009. View Article : Google Scholar
|
|
3
|
Wolf G, Chen S and Ziyadeh FN: From the
periphery of the glomerular capillary wall toward the center of
disease: podocyte injury comes of age in diabetic nephropathy.
Diabetes. 54:1626–1634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mitu GM, Wang S and Hirschberg R: BMP7 is
a podocyte survival factor and rescues podocytes from diabetic
injury. Am J Physiol Renal Physiol. 293:F1641–F1648. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patrakka J and Tryggvason K: Nephrin - a
unique structural and signaling protein of the kidney filter.
Trends Mol Med. 13:396–403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marshall SM: The podocyte: a potential
therapeutic target in diabetic nephropathy? Curr Pharm Des.
13:2713–2720. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolf G and Ziyadeh FN: Cellular and
molecular mechanisms of proteinuria in diabetic nephropathy.
Nephron Physiol. 106:26–31. 2007. View Article : Google Scholar
|
|
8
|
Kikuchi Y, Imakiire T, Yamada M, et al:
Mizoribine reduces renal injury and macrophage infiltration in
non-insulin-dependent diabetic rats. Nephrol Dial Transplant.
20:1573–1581. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams MD and Nadler JL: Inflammatory
mechanisms of diabetic complications. Curr Diab Rep. 7:242–248.
2007. View Article : Google Scholar
|
|
10
|
Ziyadeh FN and Wolf G: Pathogenesis of the
podocytopathy and proteinuria in diabetic glomerulopathy. Curr
Diabetes Rev. 4:39–45. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei X, Gong J, Zhu J, et al: Therapeutic
effects of triptolide on interleukin-10 gene-deficient mice with
colitis. Int Immunopharmacol. 8:1808–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan SC, Shum DK, Tipoe GL, Mak JC, Leung
ET and Ip MS: Upregulation of ICAM-1 expression in bronchial
epithelial cells by airway secretions in bronchiectasis. Respir
Med. 102:287–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin N, Liu C, Xiao C, et al: Triptolide, a
diterpenoid triepoxide, suppresses inflammation and cartilage
destruction in collagen-induced arthritis mice. Biochem Pharmacol.
73:136–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song HX, Gong J and Chen W: Effect of
triptolide on urinary monocyte chemottractant protein-1 in patients
with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi.
25:416–418. 2005.(In Chinese).
|
|
15
|
Ma RX, Liu LQ, Xu Y and Jiang W:
Protective effect of triptolide on renal tissues in type 2 diabetic
rats. Chinese Journal of Hypertension. 16:1120–1124. 2008.(In
Chinese).
|
|
16
|
Yamamoto Y, Maeshima Y, Kitayama H, et al:
Tumstatin peptide, an inhibitor of angiogenesis, prevents
glomerular hypertrophy in the early stage of diabetic nephropathy.
Diabetes. 53:1831–1840. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Danda RS, Habiba NM, Rincon-Choles H, et
al: Kidney involvement in a nongenetic rat model of type 2
diabetes. Kidney Int. 68:2562–2571. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo XH, Liu ZH, Li H, et al: A novel rat
model of type 2 diabetes mellitus. Chinese Journal of Nephrology
Dialysis & Transplantation. 9:351–355. 2000.(In Chinese).
|
|
19
|
Jefferson JA, Shankland SJ and Pichler RH:
Proteinuria in diabetic kidney disease: a mechanistic viewpoint.
Kidney Int. 74:22–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hauser PV, Collino F, Bussolati B and
Camussi G: Nephrin and endothelial injury. Curr Opin Nephrol
Hypertens. 18:3–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baelde HJ, Eikmans M, Lappin DW, Doran PP,
Hohenadel D, Brinkkoetter PT, van der Woude FJ, et al: Reduction of
VEGF-A and CTGF expression in diabetic nephropathy is associated
with podocyte loss. Kidney Int. 71:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mathieson PW: Update on the podocyte. Curr
Opin Nephrol Hypertens. 18:206–211. 2009. View Article : Google Scholar
|
|
23
|
Wittmann S, Daniel C, Stief A, Vogelbacher
R, Amann K and Hugo C: Long-term treatment of sirolimus but not
cyclosporine ameliorates diabetic nephropathy in the rat.
Transplantation. 87:1290–1299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eto N, Wada T, Inagi R, et al: Podocyte
protection by darbepoetin: preservation of the cytoskeleton and
nephrin expression. Kidney Int. 72:455–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Chen B, Hou XH, et al: Effects of
mycophenolate mofetil, valsartan and their combined therapy on
preventing podocyte loss in early stage of diabetic nephropathy in
rats. Chin Med J (Engl). 120:988–995. 2007.PubMed/NCBI
|
|
26
|
Chen ZH, Qin WS, Zeng CH, et al:
Triptolide reduces proteinuria in experimental membranous
nephropathy and protects against C5b-9-induced podocyte injury in
vitro. Kidney Int. 77:974–988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS
and Liu ZH: Triptolide protects podocytes from puromycin
aminonucleoside induced injury in vivo and in vitro. Kidney Int.
74:596–612. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Q, Shen W, Qin W, et al: Treatment of
db/db diabetic mice with triptolide: a novel therapy for diabetic
nephropathy. Nephrol Dial Transplant. 25:3539–3547. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tarabra E, Giunti S, Barutta F, et al:
Effect of the monocyte chemoattractant protein-1/CC chemokine
receptor 2 system on nephrin expression in streptozotocin-treated
mice and human cultured podocytes. Diabetes. 58:2109–2118. 2009.
View Article : Google Scholar
|
|
30
|
Lee EY, Chung CH, Khoury CC, et al: The
monocyte chemoattractant protein-1/CCR2 loop, inducible by
TGF-beta, increases podocyte motility and albumin permeability. Am
J Physiol Renal Physiol. 297:F85–F94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tossidou I, Starker G, Kruger J, et al:
PKC-alpha modulates TGF-beta signaling and impairs podocyte
survival. Cell Physiol Biochem. 24:627–634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takano Y, Yamauchi K, Hayakawa K, et al:
Transcriptional suppression of nephrin in podocytes by macrophages:
roles of inflammatory cytokines and involvement of the PI3K/Akt
pathway. FEBS Lett. 581:421–426. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim YH, Lee SH, Lee, Choi SW, Park JW and
Kwon TK: Triptolide inhibits murine inducible nitric oxide synthase
expression by down-regulating lipopolysaccharide-induced activity
of nuclear factor-kappa B and c-Jun NH2-terminal kinase.
Eur J Pharmacol. 494:1–9. 2004. View Article : Google Scholar
|
|
34
|
Zhou Y, Ling EA and Dheen ST:
Dexamethasone suppresses monocyte chemoattractant protein-1
production via mitogen activated protein kinase phosphatase-1
dependent inhibition of Jun N-terminal kinase and p38
mitogen-activated protein kinase in activated rat microglia. J
Neurochem. 102:667–678. 2007. View Article : Google Scholar
|
